All Brands Owned by Regeneron Pharmaceuticals, Inc.

What does Regeneron own?
Regeneron owns and markets its internally developed medicines: Eylea and Eylea HD, Libtayo, Praluent, Kevzara, Arcalyst, Evkeeza, Veopoz, Inmazeb, and Lynozyfic, and shares Dupixent economics with Sanofi. It also owns the VelocImmune antibody platform and the Regeneron Genetics Center.

Is Regeneron publicly traded?
Yes. Regeneron Pharmaceuticals trades on Nasdaq under the ticker REGN and is a member of the S&P 500 index.

Who founded Regeneron?
Leonard Schleifer, a neurologist, founded the company in 1988. George Yancopoulos joined in 1989 and built its research organization. Both men still lead the company as CEO and President/Chief Scientific Officer respectively.

Does Sanofi own part of Regeneron?
No. Sanofi is a collaboration partner, not an owner. Sanofi books global Dupixent and Kevzara sales and shares profits with Regeneron under contract. Sanofi previously held a Regeneron equity stake but sold it in 2020.

Where is Regeneron headquartered?
Regeneron is headquartered in Tarrytown, New York, on the Hudson River north of New York City. Its main manufacturing campuses are in Rensselaer, New York, and Limerick, Ireland.

What is Regeneron's biggest product?
Dupixent is the largest by global sales at $17.8 billion in 2025, though Sanofi records those sales and shares the profit. The largest product Regeneron books directly is the Eylea retinal franchise at $7.9 billion in 2025 global sales.